Insider Selling: Outset Medical, Inc. (NASDAQ:OM) CFO Sells 34,288 Shares of Stock

Outset Medical, Inc. (NASDAQ:OM) CFO Nabeel Ahmed sold 34,288 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $0.80, for a total transaction of $27,430.40. Following the transaction, the chief financial officer now directly owns 258,869 shares of the company’s stock, valued at approximately $207,095.20. This represents a 11.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Nabeel Ahmed also recently made the following trade(s):

• On Monday, January 13th, Nabeel Ahmed sold 29,031 shares of Outset Medical stock. The stock was sold at an average price of $0.81, for a total transaction of $23,515.11.
• On Tuesday, January 7th, Nabeel Ahmed sold 1,835 shares of Outset Medical stock. The shares were sold at an average price of $1.29, for a total value of $2,367.15.
• On Friday, November 15th, Nabeel Ahmed sold 4,221 shares of Outset Medical stock. The stock was sold at an average price of $0.80, for a total value of $3,376.80.

Outset Medical Stock Performance

Shares of NASDAQ OM opened at $0.86 on Friday. The company has a quick ratio of 5.04, a current ratio of 6.49 and a debt-to-equity ratio of 4.12. The firm’s 50-day moving average price is $1.01 and its two-hundred day moving average price is $1.28. Outset Medical, Inc. has a 52-week low of $0.44 and a 52-week high of $5.22. The stock has a market capitalization of $45.18 million, a P/E ratio of -0.31 and a beta of 2.05.

Institutional Trading of Outset Medical

A number of institutional investors and hedge funds have recently made changes to their positions in OM. Millennium Management LLC boosted its stake in Outset Medical by 58.8% during the 2nd quarter. Millennium Management LLC now owns 1,942,899 shares of the company’s stock valued at $7,480,000 after purchasing an additional 719,412 shares during the period. GSA Capital Partners LLP raised its holdings in shares of Outset Medical by 924.7% during the third quarter. GSA Capital Partners LLP now owns 1,111,612 shares of the company’s stock valued at $753,000 after buying an additional 1,003,135 shares during the last quarter. Marshall Wace LLP boosted its position in shares of Outset Medical by 487.8% during the second quarter. Marshall Wace LLP now owns 314,187 shares of the company’s stock worth $1,210,000 after buying an additional 260,740 shares during the period. Point72 Asset Management L.P. bought a new position in Outset Medical in the 2nd quarter worth approximately $827,000. Finally, Cubist Systematic Strategies LLC grew its holdings in Outset Medical by 228.3% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 200,939 shares of the company’s stock worth $774,000 after buying an additional 139,740 shares in the last quarter.

Analyst Ratings Changes

Separately, Royal Bank of Canada reissued a “sector perform” rating and set a $3.00 price target on shares of Outset Medical in a research report on Tuesday, January 7th.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.